N
Google TrendCOVENTRY VS NEWCASTLE (2000+) — Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:coventry vs newcastle2000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls500+afc champions league200+what's on netflix200+essie fall nail polish trends 2026200+champions league schedule500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Biogen Expands Complement" (23 stories)

Top Headline Story

Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals
Lead StoryBioPharm Internationalgeneral
May 15

Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOV01lMEJiVGh1dm5Ja2VOcXR0QmY3WkQyRlFCSmt6UUotZ3FtSDhNb29GeHZXSzB3MWVFRUx4N1BKRGdoV3A1cXFfcktsSUlUUUlMdVJVUURvQlBCU1R6WHhFQTN1WGN2OFA3QUxyU3hBVWNNWDBBXzhQWlpRMFVodHZBcWhNUUxHNGhGTzgxVmV3dVZ2bW14akx4REpTdzVLbmhMWVdWVU1hV3F5a2VDU0p5XzVvNDRHbk1sUVlvUG1CdDVtNFFpWTlScDk4Zw?oc=5" target="_blank">Biogen Expands Complement Disease Portfolio Through Acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+30m ago

coventry vs newcastle

Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats

Filter stories
2000+30m ago

levante - sevilla

Levante - Sevilla en directo

Filter stories
1000+30m ago

servicio de control de inmigración y aduanas

"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon

Filter stories
500+30m ago

indigo girls

Indigo Girls cancel show after tour bus driver dies in highway crash

Filter stories

Search Results for "Biogen Expands Complement"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

22 stories displayed
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Biogenworld

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOVEV0VlhLbzVMaGdWYjJJLVN4V0NIVnVidDk2NW9vRzVpTTNwVDBZTl9aQW9Xd0FKQ3JTeXBvcUZpSTFQNHEwN3NRX1FTeUdfdVNlYWpDZlREb1lOd0RVemRNUG5WRnlHN3R1czVXN2NteVFqeV9hYzZybXZZWVkwTDZSNlFrQmJtNFBOUjZqZU9jRXFRRmFhNE1oNkVfM1ZrWEFIZ2FQclpuYmRYV09jVDdGSDZKZ1BPYnhXZHNIZw?oc=5" target="_blank">Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
Biogen Completes Apellis Acquisition to Expand Rare Disease and Nephrology Portfolio
citybizgeneral

Biogen Completes Apellis Acquisition to Expand Rare Disease and Nephrology Portfolio

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOb2ZoamRLOGdBSlp5REFMOW43ZVNsZVVhMHdyTFhteTh2VUpjMUVselpNVm5ydnpqenNWNHpremVTQ3BKMzhOYWNxOWw3ZXBzcmN4X1M2RWhIX1daeGcxNzFrTXNWMzlHT1U3aVMwSjByWW9URzUzb3c4dl9LZ19NOThWeFlNcHZyT1pHYXllVnJjYWxCZU1RQ1Q3VGl5Sm1xemJCRnRrQkpQYTNEQUR2NnBXSHZtNW5vRXpwOXAtZkQ?oc=5" target="_blank">Biogen Completes Apellis Acquisition to Expand Rare Disease and Nephrology Portfolio</a>  <font color="#6f6f6f">citybiz</font>

Read Full StoryMore like this
Biogen to acquire Apellis in $5.6 billion deal
Ophthalmology Timespolitics

Biogen to acquire Apellis in $5.6 billion deal

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxOVDh3dnlNZVhZUWFucm5ldlo5VjNKMlhVYnJ2TGZCeXFtWkVTN25La0JyRlJjQXJqYXNaSEc3V1FHbXdZNUh6RXdVMmMzT0VlX0pBeF9xeHBHdldWUW04dlJQdW1wd0lFdmx4ejM4LXJsOXNvcmVjTEZjTmFPQmtidDlJMW5pV1lEOVhYOXBn?oc=5" target="_blank">Biogen to acquire Apellis in $5.6 billion deal</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals
Pharmaceutical Executivepolitics

Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxNMlJ1RkJBdV9qbXZlc0d3WnJpSnZiVjFjaXdtUUFxRDduNm9qbUNvb1hPRWd3VkJMaktGMnhKaUdCN3MzZlpfVm1NZ1p6Q3ZwZVp5YTIyTUtDd05XdFpBdmdhRmRjR05pWjhYbDhsTEdoRDdoRWEzRFdEQnZWbTJRenVnNUd4NzA?oc=5" target="_blank">Biogen Enters $5.6 Billion Agreement to Acquire Apellis Pharmaceuticals</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance
Yahoo Financegeneral

Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQQ19wV1cxYTJNa0JVbFFSalVudmRMdWcwbHgwZk1DRTV2WUVJY2hOR0p4NUU3dk01ckgwSUJyQkFCbWVaZ0JiRms3QzdScmJNNVBab1BnS0I3U1pVUXUxMnpSbUlMMXBMb1VYVlVPS0hDeVRMQURmNFlFaFZlVl9PbzJDbGJ1SmVlYVRfUERVOG9XV1RTRlZTZHRFVExtM2s5TXVIV1FzQ01zanFZZkE?oc=5" target="_blank">Biogen Expands Targeted Therapy Pipeline With Apellis Deal And Alloy Alliance</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Biogen makes up to $1B immuno play with RayThera takeover
BioSpaceworld

Biogen makes up to $1B immuno play with RayThera takeover

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPaFpjT3pwRklpWUpIemtQbzYtZllSaTJmWmd5OExWMzNHZkJTQUwwQmxuS2JGNFRNUk14S1laZkVYRzNrckR6SEZzdk5NcnBMeU5nOFBaeVpJVGJvT2UweUZmRTJVMmpreU96dlRIVjhSMTNUUk1WSFZSUDNSX1RsUjU3YmNsYmJvdWpnMEZaOEFsc25EVF9aUER1MjI5TWs?oc=5" target="_blank">Biogen makes up to $1B immuno play with RayThera takeover</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
Biogen Completes Acquisition of Apellis Pharmaceuticals
GlobeNewswiregeneral

Biogen Completes Acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQNWk2Vzk5WlpOcmpRc0VvQnZLZ09xR19LZTRBRU95MzBreUlBOFpKQ2hmeHFkZjVUazZsUjZLYlpaMlN5QVB2dFp1YkduN3VCM19VVTNRQ05jcWJVZHJDbnBKWGdSWUFtMHZZZmtsZktxT2VRNE1zX3BYVlg2VkxIdmZnQzliUUptRkVCcHphRzRjT3dxM2ZScGlTRUxWNzFzSHJ1TlgzOWFYWWY0TnVkdFYzMGF0ZUhxNXRfX1NpTGNoMmRoZHc?oc=5" target="_blank">Biogen Completes Acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Biogen expands control of CD38 antibody felzartamab across global markets
Drug Discovery Newsmarkets

Biogen expands control of CD38 antibody felzartamab across global markets

<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxPMUV0bGlIT2FTbVZ0d1hQWnZPRFBBbGxjcTJPc1NIWjlzQmhZSnZfQnBJd2FSaDNQS0UxS2J2VXJhby1aRlozRlgtS2Q0UVNlT3BfekR2VjNmTzBqYTJFU0JISTZiYzBuMnRmak5mUzFfbkEzMWRaUFlFcUxMTnZGbXdxdVFqNzV5Y1VYSWprb2Q0TTVEVlZLNWxNU2ROUkkwb0w4eTM0aGlaU1NFRUlLU1BNbw?oc=5" target="_blank">Biogen expands control of CD38 antibody felzartamab across global markets</a>  <font color="#6f6f6f">Drug Discovery News</font>

Read Full StoryMore like this
Why Biogen Is Paying $5.6B to Buy Apellis Pharma
MedCity Newsgeneral

Why Biogen Is Paying $5.6B to Buy Apellis Pharma

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxQVll0dml1NGViZVZKR2k1MTRaSjdmTi1tMi13REN6SlQzWE5fZ2VMMk85ODRkQlFXVl9LYy1TRFgzVzRXcTd2UWRNUVBILS1TRHo1cDRhSGJTZkV0RkFITjdTcVBzNVRWRXUxWnJmLUdubm9vVUlLTlJZSDEtLXk5RFl0YXhwYms?oc=5" target="_blank">Why Biogen Is Paying $5.6B to Buy Apellis Pharma</a>  <font color="#6f6f6f">MedCity News</font>

Read Full StoryMore like this
Biogen: $5.6 Billion Acquisition Of Apellis To Expand Immunology And Rare Disease Portfolio
Pulse 2.0politics

Biogen: $5.6 Billion Acquisition Of Apellis To Expand Immunology And Rare Disease Portfolio

<a href="https://news.google.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?oc=5" target="_blank">Biogen: $5.6 Billion Acquisition Of Apellis To Expand Immunology And Rare Disease Portfolio</a>  <font color="#6f6f6f">Pulse 2.0</font>

Read Full StoryMore like this
Biogen to acquire Apellis for $5.6bn
Financier Worldwidegeneral

Biogen to acquire Apellis for $5.6bn

<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE15N0lFbXhaMV82WC0wZGZXVl9Hb21qN1A2cGc2dVZIOUViLUcxT2VCMHdmUVo5WHlEaVlPNEJnX3UzU29Hel9ZQ1p6YjFUYmpRYy1QZlkwa3RoNHJqNEtzbEp5OXIwNXh6eHlpQ3ZwZ2lKS3FtYldFeA?oc=5" target="_blank">Biogen to acquire Apellis for $5.6bn</a>  <font color="#6f6f6f">Financier Worldwide</font>

Read Full StoryMore like this
Biogen completes acquisition of Apellis Pharmaceuticals
Ophthalmology Timesgeneral

Biogen completes acquisition of Apellis Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPNXJMNVJXX0t6M0xBVkJMTC1tN3hEXzhFYi1paGlnZWh4Z3Z5VUgwNFpHUE5BeDJKbm9abjdsZVU0aXBiRVVCQ3BJYldIem90b1JpUXhKMlpuTVFCQ29pWHJaZUhRRFN1alA2cDR2djV5c284OTBoVkNGSjluV1Q0WlRSYXZvTTh3bmpVaHZtY2xmbFNUZVdIU3pQcw?oc=5" target="_blank">Biogen completes acquisition of Apellis Pharmaceuticals</a>  <font color="#6f6f6f">Ophthalmology Times</font>

Read Full StoryMore like this
The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion
BioPharm Internationalgeneral

The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPeXBVVmxEa1FYRE00QWlGNWhqeE5uM0NTLTFEZEV3Wk9TU0lWN2hEN1dMT0ltM0xwQWlieEdzV1NXYjA2bXUwQldOWjJxOGctSWVrQkdldFl2OXdEdEpJQTl1V0lka2ZQNTlmdVdiMEgzVWJlb3ZpRGs1bGZVbXRydWxMdzB0Q2ppMklTRHNCYW44M3IycU4zVy1IWVZqODQ0enpWWThiOWhKSkQ4dEFTdHQwYzQ?oc=5" target="_blank">The BioPharm Brief: Oncology Momentum, CAR-T Advances, Strategic Expansion</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology
Fierce Biotechworld

Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOWkZUcHk4MDJLdWZkekdUd0x4SFQxMEp5Zk8zakJ1UldkeXdDcV9RV2JSdUxyeDZfU3pmdUNOV0gyZjM1ZWJUMk8yVkY3VHdpTExNMVNpY0JVaGNHOG5ndEpGRjlQSVlLUzdYMFY0eUlLQ2hTdUVkVWpGTEd6UEZ0ZGgzUUJRMFAzdEE5SGprLTQ0T3VIaUhzazdNT3lqbmo1?oc=5" target="_blank">Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology</a>  <font color="#6f6f6f">Fierce Biotech</font>

Read Full StoryMore like this
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
BioPharma Diveworld

Biogen adds more immune drugs in $1B buyout of secretive startup RayThera

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQSkpMbDFKSHJzbmZlZkMxSjVvanFpdDNIT0xtX1NhWGJ6T3Baa2p6X3I4R3hUVXcyWG03Z3hIVVZCcVItXzc5YlY5bndRWXhkSF9IakVDTWhabUdPNFh0eVhFUVlTMjZyS0tSbHFZWXdNajdUVS1lNWFVYzVQWEFkZUZGeXNCN2k5bHpwdA?oc=5" target="_blank">Biogen adds more immune drugs in $1B buyout of secretive startup RayThera</a>  <font color="#6f6f6f">BioPharma Dive</font>

Read Full StoryMore like this
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
GlobeNewswireworld

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPd3k5WmpqeXFUNkJLR2s1X2RDNi1RS1Y3Qnd3TWp6SEtyNVlQX3o3ZnZtTFdNc2duNjZTazhwR3lkLV8tdVRxT0RBZ1cyOTZUYzJzVmxZd1VuWW1BWDhpcnpFSjVUMzFiZkZyenZyVDZEX3JVc3JmZ0szSDNzQThBOWhKa1NBak12UndxemVFdUhFVVJjU2hkRnFPejVVazVZenNibzFnNFRzRHg0aW5jSHp1OGN1dXhlb3FKeHlWQU51UURPSzd0MGhXTThwS2VsSWJHUnZ6N0FaYmNCbXQ5VTlFd21fSFpwU1R5Tg?oc=5" target="_blank">Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Biogenscience

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNODg4c1hDVWJ0SER3N1RSTXlyN09JbUJLODRhN1FxMGJmeFRwQTQ1TGo2YTlrZHcwaWQtQ21HR3VwZ3RKSFBiVktfUjhPR0sxOFhzWTJ3WmlXaVZvUEx1cUR5V1VhMXBCYWtocGU5QnFGN3MxY1h0N1QwRlZYbU9od2FwUWNmaEg1UWgyMUk4U1lZaVFtZlNwcDZmYW1QaE93bUNLMXBZeFZDOF9lVHF1al9tRW5weFcwcUFpVmZyZ1hqUFZ0eEVV?oc=5" target="_blank">Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
Biogentech

Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQSExQY2tKZ0Z5amVCWGtQNlRLZml3LTFzX2k0MEw3bFN6V1VaMjBGOXQ3NHdCSGc1XzRnZnpZLVhyREhVTUp1OFp3cEFvTmlUQUNQQjdSalQ5WkZRbm1qRlZTRmVwVHd5UTFhZWxlRWp0Uk9xWmtIMGp4bUZKMTRXdVZmZ0hTRG5zeGVUTWJvTU1PNVdYeTNvLVlwLVpHbUtqVW55aFFZRDM2TzVNQi1LNFd5QTFCMUdReG1PcHJha1BqUjRR?oc=5" target="_blank">Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
Protease medicines to catalyse change in complement-targeting therapies
Naturegeneral

Protease medicines to catalyse change in complement-targeting therapies

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBDSENRU1pkNzd1c2pQcDNnckVnc3FZWFVVbU9vMzBPNzc1bVRDLXJXVUVKd2xkR3JKa1RyaEZMblZXWmp5QnBGS0dROFZZcm9wMmRWcUYzSE1ZZ2VEOFNj?oc=5" target="_blank">Protease medicines to catalyse change in complement-targeting therapies</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals
Biogentech

Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPUWdZTWllZ0JTRU8yRTVNQjNpUGZTNDlUeWZvOTF5WmlLNzdYSnRkWWtuTkEyaTFMb3l2TmhaWFlnWmdzMEVYTmNhLWtsbFJoS2dtenpLUW9kdEgwZl9WOU8tY25zNy16alpmLU05YksxTGJ6T3c0emJ6UEV6eEc1NWlFSU43bEY5R2Q4UWItWEgyajRNS2dRU3JETTIzeXBNTjJrcUo3eDFzaW82R2xRWFVYNjJGTDM1Y05mY0Fn?oc=5" target="_blank">Biogen Idec to Expand Neuropathic Pain Portfolio with the Acquisition of Convergence Pharmaceuticals</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
EU authorises intramuscular administration of Biogen’s Plegridy for MS
PharmaTimesgeneral

EU authorises intramuscular administration of Biogen’s Plegridy for MS

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPR1I0dlVVQjk3aS1SaWZLUzlLd29tNTNIZmlQZnJ1dUlPUHpJVlV6RlhyVDZxUGpLZ3FaeHFQZlVmQ09MWFUwaDlNZDdJVFpBUThtcklzWXNmUG85UGVHR2paVG1xQXBuak9ORC1BWnFKR3lnQmhvajNyMnBXdmRUaE1aS3lhQU9HdmFramtNRTlMR3QtdUdhSVNobW4zSnE5eE5xRC02emYzSVE?oc=5" target="_blank">EU authorises intramuscular administration of Biogen’s Plegridy for MS</a>  <font color="#6f6f6f">PharmaTimes</font>

Read Full StoryMore like this
Apellis shares explode 140% on Biogen’s $5.6B bid
Rolling Outgeneral

Apellis shares explode 140% on Biogen’s $5.6B bid

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE94WTh2RWNYYWdYUm1kRERIRTJSdHQ3NHlfRjNwR09BN2cxNmJKdTR3TkxkcklaMmduQjU2bl9JRVdCLUM1aklrY2ZCMnAwLVVkS1BpcDFFVF9CZFJwNU9KbVgyUm5nOXk0VGgxaVdyTXRkZzlwODlNblRhVlZSZw?oc=5" target="_blank">Apellis shares explode 140% on Biogen’s $5.6B bid</a>  <font color="#6f6f6f">Rolling Out</font>

Read Full StoryMore like this
"Biogen Expands Complement" — Live Google News Trends & Headlines